Human Recombinant Leptin Administration as a Potential Obesity Therapy

Abstract

Obesity is an escalating global health problem and established cardiovascular risk factor for the development of cardiovascular and metabolic diseases. Leptin derived from the adipose tissue acts centrally to suppress appetite and increase energy expenditure, therefore leptin resistance is considered as an important mechanism for the onset and maintenance of obesity; Leptin analogues as well as leptin receptor blockers have been candidates for the treatment of obesity, however clinical trials in obese populations have yielded variable results. Given specific circumstances in obese subjects could optimize the beneficial actions of the hormone and minimize its deleterious effects. In this review, human recombinant leptin (pegylated polyethylene glycol recombinant human leptin (PEG-OB) and recombinant methionyl human leptin (r-metHuLeptin) is developed to control resistant and morbid obesity will be discussed. Keywords: Obesity, leptin, pegylated human recombinant leptin, recombinant methionyl human leptin, myocardial hypertrophy, dyslipidemia, hyperleptinemia, hypothalamic pro-opiomelanocortin, anorectic effects, neuroendocrine, hypothalamus, thermogenesis, sympathoectomy, retinopathy, nephropathy, genetic mutation, myocardium, atherosclerosis, thrombosis, arterial hypertension, neointinal hyperplasia, blood-brain barrier, norepinephrine spillover, melanocortin system, neuropeptide mediators, Pegylated Polyethylene Glycol, pramlintide, triglyceride, somatotropic axes, plasminogen activator, adiponectin, ghrelin